EP2240028A4 - Organische verbindungen - Google Patents
Organische verbindungenInfo
- Publication number
- EP2240028A4 EP2240028A4 EP08856780A EP08856780A EP2240028A4 EP 2240028 A4 EP2240028 A4 EP 2240028A4 EP 08856780 A EP08856780 A EP 08856780A EP 08856780 A EP08856780 A EP 08856780A EP 2240028 A4 EP2240028 A4 EP 2240028A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- organic compounds
- compounds
- organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1204507P | 2007-12-06 | 2007-12-06 | |
PCT/US2008/013410 WO2009073210A1 (en) | 2007-12-06 | 2008-12-06 | Organic compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2240028A1 EP2240028A1 (de) | 2010-10-20 |
EP2240028A4 true EP2240028A4 (de) | 2012-02-08 |
EP2240028B1 EP2240028B1 (de) | 2016-07-20 |
Family
ID=40718054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08856780.5A Active EP2240028B1 (de) | 2007-12-06 | 2008-12-06 | Pyrazolopyrimidine-4,6-dione derivate und deren Anwendung als Pharmaceutika |
Country Status (11)
Country | Link |
---|---|
US (2) | US8846693B2 (de) |
EP (1) | EP2240028B1 (de) |
JP (1) | JP5701608B2 (de) |
KR (1) | KR20100094551A (de) |
CN (1) | CN101969774A (de) |
AU (1) | AU2008331833A1 (de) |
CA (1) | CA2707218A1 (de) |
ES (1) | ES2588238T3 (de) |
IL (1) | IL206097A0 (de) |
MX (1) | MX2010006208A (de) |
WO (1) | WO2009073210A1 (de) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4439143A1 (de) | 1994-11-03 | 1996-05-09 | Philips Patentverwaltung | Drehanoden-Röntgenröhre mit einem Gleitlager |
WO2003020702A2 (en) | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
AU2006255028B2 (en) | 2005-06-06 | 2012-04-19 | Intra-Cellular Therapies, Inc. | Organic compounds |
US9255099B2 (en) | 2006-06-06 | 2016-02-09 | Intra-Cellular Therapies, Inc. | Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors |
JP2010509399A (ja) * | 2006-11-13 | 2010-03-25 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
JP5837278B2 (ja) | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規使用 |
HRP20131073T1 (hr) | 2007-12-06 | 2014-01-31 | Takeda Pharmaceutical Company Limited | Organski spojevi |
EP2370080A1 (de) * | 2008-12-02 | 2011-10-05 | University of Utah Research Foundation | Pde1 als zieltherapeutikum bei herzkrankheiten |
MA32940B1 (fr) | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
BRPI0922808A2 (pt) | 2008-12-06 | 2018-05-29 | Intracellular Therapies Inc | compostos orgânicos |
MA32937B1 (fr) * | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
CA2740396A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
MX2011005935A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
ES2638912T3 (es) | 2008-12-06 | 2017-10-24 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
EP2400970A4 (de) | 2009-02-25 | 2012-07-18 | Intra Cellular Therapies Inc | Pde-1-hemmer für augenleiden |
WO2010132127A1 (en) | 2009-05-13 | 2010-11-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2011016861A2 (en) | 2009-08-05 | 2011-02-10 | Intra-Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
WO2011043816A1 (en) | 2009-10-08 | 2011-04-14 | Intra-Cellular Therapies, Inc. | Phosphodiesterase 1-targeting tracers and methods |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
WO2011153138A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2011153136A1 (en) * | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2011153135A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN103012287B (zh) * | 2012-12-24 | 2015-06-17 | 济南圣泉唐和唐生物科技有限公司 | 6-氯-3-甲基脲嘧啶的制备方法 |
WO2014127331A1 (en) | 2013-02-17 | 2014-08-21 | Intra-Cellular Therapies, Inc. | Novel uses |
JP6437519B2 (ja) | 2013-03-15 | 2018-12-12 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
ES2717688T3 (es) | 2013-03-15 | 2019-06-24 | Intra Cellular Therapies Inc | Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP |
US9849132B2 (en) | 2014-01-08 | 2017-12-26 | Intra-Cellular Therapies, Inc. | Products and pharmaceutical compositions |
JP6810613B2 (ja) | 2014-06-20 | 2021-01-06 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
JP6591530B2 (ja) | 2014-08-07 | 2019-10-16 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN107106563B (zh) | 2014-09-17 | 2021-05-25 | 细胞内治疗公司 | 化合物和方法 |
BR112017012007B1 (pt) | 2014-12-06 | 2022-11-01 | Intra-Cellular Therapies, Inc | Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2 |
MX2017007377A (es) | 2014-12-06 | 2017-11-06 | Intra-Cellular Therapies Inc | Compuestos organicos. |
US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
JP7134168B6 (ja) | 2016-09-12 | 2024-02-02 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
CN110337437B (zh) | 2016-12-28 | 2023-02-03 | 达特神经科学有限公司 | 作为pde2抑制剂的取代的吡唑并嘧啶酮化合物 |
EP3617208A4 (de) * | 2017-04-27 | 2020-08-26 | Takeda Pharmaceutical Company Limited | Heterocyclische verbindung |
CN109422749B (zh) * | 2017-08-21 | 2023-01-24 | 重庆医药工业研究院有限责任公司 | 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物 |
JP7254078B2 (ja) | 2017-11-27 | 2023-04-07 | ダート・ニューロサイエンス・エルエルシー | Pde1阻害剤としての置換フラノピリミジン化合物 |
JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
US11628171B2 (en) | 2019-03-13 | 2023-04-18 | Children's Medical Center Corporation | Method for treating brain or nerve injury |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0166054A1 (de) * | 1983-12-14 | 1986-01-02 | Takeda Chemical Industries, Ltd. | 3-Aminopyrazolo[3,4-d]pyrimidinderivate und deren Herstellung |
EP0237289A2 (de) * | 1986-03-14 | 1987-09-16 | Takeda Chemical Industries, Ltd. | Pyrazolo[3,4-d]pyrimidinderivate, ihre Herstellung und Verwendung |
WO1998046606A1 (en) * | 1997-04-15 | 1998-10-22 | Astra Pharmaceuticals Ltd. | Novel compounds |
US6133273A (en) * | 1998-05-08 | 2000-10-17 | American Home Products Corporation | Pyrazolopyrimidine-2,4-dione sulfonamides |
WO2003002567A1 (en) * | 2001-06-28 | 2003-01-09 | Astrazeneca Ab | New pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections |
WO2007143705A2 (en) * | 2006-06-06 | 2007-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US540934A (en) * | 1895-06-11 | Sheej-iron heating-stove | ||
US3689863A (en) * | 1969-12-08 | 1972-09-05 | Matsushita Electric Ind Co Ltd | Voltage dependent resistors in a surface barrier type |
GB1447426A (en) * | 1974-03-20 | 1976-08-25 | Lepetit Spa | Pyrrolo 3,4-d- pyrimidines and methods for their preparation |
JPS6032638B2 (ja) | 1976-09-01 | 1985-07-29 | 武田薬品工業株式会社 | 3−アミノピラゾロ〔3,4−d〕ピリミジン誘導体 |
JPS58500966A (ja) | 1981-04-22 | 1983-06-09 | ビイク グルデン ロンベルク ヒエ−ミツシエ フアブリ−ク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 新規ピラゾロ〔3,4−d〕ピリミジン、その製法及びこれを含有する医薬品 |
US4663326A (en) * | 1985-04-04 | 1987-05-05 | Warner-Lambert Company | Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs |
US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
JPS6310788A (ja) | 1986-03-14 | 1988-01-18 | Takeda Chem Ind Ltd | 3−アミノピラゾロ〔3,4−d〕ピリミジン誘導体 |
US4912104A (en) | 1987-08-31 | 1990-03-27 | Takeda Chemical Industries, Ltd. | Tricyclic fused pryimidine derivatives, and their use as pharmaceuticals |
JPH01265027A (ja) | 1988-04-14 | 1989-10-23 | Takeda Chem Ind Ltd | 肝疾患治療剤 |
EP0353941A3 (de) | 1988-08-02 | 1991-05-02 | Takeda Chemical Industries, Ltd. | 3-Aminopyrazol [3,4-d]pyrimidinderivate enthaltendes Arzneimittel gegen Psoriasis |
JP3116230B2 (ja) | 1989-02-15 | 2000-12-11 | 武田薬品工業株式会社 | 三環式縮合ピリミジン誘導体 |
JPH02289518A (ja) | 1989-02-15 | 1990-11-29 | Takeda Chem Ind Ltd | アデノシン拮抗剤 |
KR920004437B1 (ko) | 1989-09-12 | 1992-06-05 | 삼성전자 주식회사 | 금전등록기의 거래선 관리방법 |
US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
NZ238609A (en) | 1990-06-21 | 1993-12-23 | Schering Corp | Polycyclic guanine derivatives; preparation, pharmaceutical compositions, |
US5409934A (en) | 1990-12-21 | 1995-04-25 | Smith; David G. | Xanthine derivatives |
US5202328A (en) * | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
US5223501A (en) * | 1991-05-10 | 1993-06-29 | Merck & Co., Inc. | Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists |
US5294612A (en) * | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
JPH08507068A (ja) * | 1993-02-26 | 1996-07-30 | シェリング・コーポレーション | 2−ベンジル−多環式グアニン誘導体およびそれらの製造方法 |
GB9315017D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
GB9626643D0 (en) | 1996-12-21 | 1997-02-12 | Astra Pharma Prod | Compounds |
DE19709126A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Arylamin-, -oxy-, -thio-substituierte Dihydropurinone und Pyrazolopyrimidine |
IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
DE69943144D1 (de) * | 1998-03-31 | 2011-03-03 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
US6166019A (en) * | 1998-07-16 | 2000-12-26 | Abbott Laboratories | Piperazinyl pyrimidine dione compounds selective for adrenoceptors |
ATE253915T1 (de) * | 1999-06-30 | 2003-11-15 | Merck & Co Inc | Src-kinase hemmende verbindungen |
DE19931206A1 (de) | 1999-07-07 | 2001-01-11 | Stief Christian | Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
SK4562002A3 (en) * | 1999-10-11 | 2003-04-01 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
IL139073A0 (en) * | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
IL139457A0 (en) | 1999-11-08 | 2001-11-25 | Pfizer | Compounds for the treatment of female sexual dysfunction |
MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
US20020006926A1 (en) * | 2000-04-19 | 2002-01-17 | Roylance H. H. | Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease |
ES2241994T3 (es) | 2001-03-16 | 2005-11-01 | Pfizer Inc. | Compuestos pirazolo(4,3-d)pirimidinona como inhibidores de gmpc. |
WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
CN1781920A (zh) | 2001-08-28 | 2006-06-07 | 先灵公司 | 多环鸟嘌呤磷酸二酯酶v抑制剂 |
WO2003020702A2 (en) | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
SE0203825D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
US20050048573A1 (en) * | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
WO2004087906A1 (en) * | 2003-03-31 | 2004-10-14 | Pfizer Products Inc. | Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
AU2004226353A1 (en) * | 2003-04-01 | 2004-10-14 | Laboratoires Serono Sa | Inhibitors of phosphodiesterases in infertility |
WO2005009343A2 (en) | 2003-06-06 | 2005-02-03 | Endacea, Inc. | A1 adenosine receptor antogonists |
US7557113B2 (en) * | 2003-08-26 | 2009-07-07 | Teijin Pharma Limited | Substituted pyrrolo[3,2-d]pyrimidine derivatives |
EP1680424A2 (de) * | 2003-09-05 | 2006-07-19 | Neurogen Corporation | Heteroarylkondensierte pyridine, pyrazine und pyrimidine als crf1-rezeptorliganden |
AU2006255028B2 (en) * | 2005-06-06 | 2012-04-19 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2007025103A2 (en) | 2005-08-23 | 2007-03-01 | Intra-Cellular Therapies, Inc. | Organic compounds for treating reduced dopamine receptor signalling activity |
US20100022571A1 (en) | 2005-09-16 | 2010-01-28 | Palle Venkata P | Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors |
JP2009512711A (ja) * | 2005-10-21 | 2009-03-26 | ブレインセルス,インコーポレイティド | Pde阻害による神経新生の調節 |
EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
US20070286890A1 (en) | 2006-06-07 | 2007-12-13 | John Garnett Walt | Eyelash applicator and method |
WO2008055959A1 (en) * | 2006-11-09 | 2008-05-15 | Galapagos N.V. | Novel compounds useful for the treatment of degenerative & inflammatory diseases |
JP2010509399A (ja) * | 2006-11-13 | 2010-03-25 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
JP5837278B2 (ja) * | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規使用 |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
HRP20131073T1 (hr) * | 2007-12-06 | 2014-01-31 | Takeda Pharmaceutical Company Limited | Organski spojevi |
TW201004957A (en) | 2008-04-22 | 2010-02-01 | Schering Corp | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use |
MX2011005935A (es) * | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
MA32940B1 (fr) * | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
BRPI0922808A2 (pt) * | 2008-12-06 | 2018-05-29 | Intracellular Therapies Inc | compostos orgânicos |
ES2638912T3 (es) * | 2008-12-06 | 2017-10-24 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
MA32937B1 (fr) * | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
CA2740396A1 (en) * | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2400970A4 (de) * | 2009-02-25 | 2012-07-18 | Intra Cellular Therapies Inc | Pde-1-hemmer für augenleiden |
WO2010132127A1 (en) * | 2009-05-13 | 2010-11-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2011043816A1 (en) * | 2009-10-08 | 2011-04-14 | Intra-Cellular Therapies, Inc. | Phosphodiesterase 1-targeting tracers and methods |
WO2011153135A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2011153138A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
TW201206937A (en) * | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
WO2011153136A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
-
2008
- 2008-12-06 WO PCT/US2008/013410 patent/WO2009073210A1/en active Application Filing
- 2008-12-06 CA CA2707218A patent/CA2707218A1/en not_active Abandoned
- 2008-12-06 AU AU2008331833A patent/AU2008331833A1/en not_active Abandoned
- 2008-12-06 ES ES08856780.5T patent/ES2588238T3/es active Active
- 2008-12-06 JP JP2010536935A patent/JP5701608B2/ja active Active
- 2008-12-06 EP EP08856780.5A patent/EP2240028B1/de active Active
- 2008-12-06 US US12/746,231 patent/US8846693B2/en active Active
- 2008-12-06 KR KR1020107014665A patent/KR20100094551A/ko not_active Application Discontinuation
- 2008-12-06 MX MX2010006208A patent/MX2010006208A/es not_active Application Discontinuation
- 2008-12-06 CN CN2008801262377A patent/CN101969774A/zh active Pending
-
2010
- 2010-05-31 IL IL206097A patent/IL206097A0/en unknown
-
2014
- 2014-09-22 US US14/492,810 patent/US20150197524A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0166054A1 (de) * | 1983-12-14 | 1986-01-02 | Takeda Chemical Industries, Ltd. | 3-Aminopyrazolo[3,4-d]pyrimidinderivate und deren Herstellung |
EP0237289A2 (de) * | 1986-03-14 | 1987-09-16 | Takeda Chemical Industries, Ltd. | Pyrazolo[3,4-d]pyrimidinderivate, ihre Herstellung und Verwendung |
WO1998046606A1 (en) * | 1997-04-15 | 1998-10-22 | Astra Pharmaceuticals Ltd. | Novel compounds |
US6133273A (en) * | 1998-05-08 | 2000-10-17 | American Home Products Corporation | Pyrazolopyrimidine-2,4-dione sulfonamides |
WO2003002567A1 (en) * | 2001-06-28 | 2003-01-09 | Astrazeneca Ab | New pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections |
WO2007143705A2 (en) * | 2006-06-06 | 2007-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
Non-Patent Citations (1)
Title |
---|
See also references of WO2009073210A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2008331833A1 (en) | 2009-06-11 |
US20150197524A1 (en) | 2015-07-16 |
KR20100094551A (ko) | 2010-08-26 |
WO2009073210A1 (en) | 2009-06-11 |
CN101969774A (zh) | 2011-02-09 |
EP2240028A1 (de) | 2010-10-20 |
JP5701608B2 (ja) | 2015-04-15 |
MX2010006208A (es) | 2010-12-21 |
EP2240028B1 (de) | 2016-07-20 |
ES2588238T3 (es) | 2016-10-31 |
IL206097A0 (en) | 2010-11-30 |
CA2707218A1 (en) | 2009-06-11 |
US20100273753A1 (en) | 2010-10-28 |
JP2011506320A (ja) | 2011-03-03 |
US8846693B2 (en) | 2014-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1208218A1 (en) | Organic compounds | |
IL206165A0 (en) | Organic compounds | |
IL206097A0 (en) | Organic compounds | |
HK1141285A1 (en) | Organic compounds | |
EP2367430A4 (de) | Organische verbindungen | |
EP2367431A4 (de) | Organische verbindungen | |
EP2358723A4 (de) | Organischen verbindungen | |
EP2367429A4 (de) | Organische verbindungen | |
EP2358204A4 (de) | Organischen verbindungen | |
EP2367428A4 (de) | Organische verbindungen | |
IL206233A0 (en) | Organic compounds | |
ZA201002336B (en) | Organic compounds | |
GB0718806D0 (en) | Organic compounds | |
GB0704230D0 (en) | Organic compounds | |
GB0817933D0 (en) | Organic compounds | |
GB0705944D0 (en) | Organic compounds | |
GB0705931D0 (en) | Organic compounds | |
GB0822091D0 (en) | Organic compounds | |
GB0709017D0 (en) | Organic compounds | |
GB0713581D0 (en) | Organic compounds | |
GB0704231D0 (en) | Organic compounds | |
GB0713860D0 (en) | Organic compounds | |
GB0704233D0 (en) | Organic compounds | |
GB0709015D0 (en) | Organic compounds | |
GB0709016D0 (en) | Organic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100706 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120112 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/18 20060101ALI20120105BHEP Ipc: A01N 43/56 20060101AFI20120105BHEP Ipc: A61P 25/16 20060101ALI20120105BHEP Ipc: A61P 25/22 20060101ALI20120105BHEP Ipc: A61P 15/00 20060101ALI20120105BHEP Ipc: A61P 9/04 20060101ALI20120105BHEP Ipc: A61P 37/00 20060101ALI20120105BHEP Ipc: A61P 35/00 20060101ALI20120105BHEP Ipc: A61P 25/28 20060101ALI20120105BHEP Ipc: A61P 25/24 20060101ALI20120105BHEP Ipc: A61K 31/519 20060101ALI20120105BHEP Ipc: C07D 487/04 20060101ALI20120105BHEP |
|
17Q | First examination report despatched |
Effective date: 20120921 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160205 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 813217 Country of ref document: AT Kind code of ref document: T Effective date: 20160815 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: INTRA-CELLULAR THERAPIES, INC. |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008045255 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SERVOPATENT GMBH, CH Ref country code: ES Ref legal event code: FG2A Ref document number: 2588238 Country of ref document: ES Kind code of ref document: T3 Effective date: 20161031 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160720 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 813217 Country of ref document: AT Kind code of ref document: T Effective date: 20160720 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161020 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161021 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161121 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008045255 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161020 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
26N | No opposition filed |
Effective date: 20170421 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161206 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20171212 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20081206 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161206 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181231 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20221111 Year of fee payment: 15 Ref country code: GB Payment date: 20221027 Year of fee payment: 15 Ref country code: FR Payment date: 20221110 Year of fee payment: 15 Ref country code: DE Payment date: 20221102 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230110 Year of fee payment: 15 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230517 |